

CURRICULUM VITAE

Name: MELANIE B. THOMAS M.D, M.S.

Office Address: Hollings Cancer Center
86 Jonathan Lucas Street
MSC 955
Charleston, SC 29425

Citizenship and/or Visa Information: United States Citizen

Education:

Boston College, Boston, Massachusetts, B.A., 1975, Biology

Harvard University, Cambridge, Massachusetts, M.S., 1982, Engineering

Boston University School of Medicine, Boston, Massachusetts, 1996, M.D.

Internship:

Harvard Medical School, Beth Israel-Deaconess Medical Center, Boston Massachusetts,
Internal Medicine, 1996-1999

Residencies or Post Doctoral:

Harvard Medical School, Beth Israel-Deaconess Medical Center, Boston Massachusetts,
1996-1999

Postdoctoral Fellowship, University of Texas M.D. Anderson Cancer Center, Houston,
Texas,
1999-2002

Specialty/Board Certification: Internal Medicine **Date:** October 2001
Medical Oncology **Date:** January 2005

Licensure: Texas **Date:** 2001
South Carolina **Date:** 2008

Faculty Appointments:

2002–2008, Assistant Professor, University of Texas M. D. Anderson Cancer Center,
Gastrointestinal Medical Oncology Department

2008 – Present, Grace E. DeWolff Chair in Medical Oncology, Medical University of South
Carolina

2008-Present Associate Professor, Division of Hematology/Oncology, Department of Medicine,
Medical University of South Carolina, Charleston, SC

2008-Present Associate Director of Clinical Investigations, Hollings Cancer Center, Medical
University of South Carolina

Administrative Appointments:

Hospital Appointments/Privileges:

2001, Inactive, LBJ Hospital

2002-2008, Inactive, University of Texas M.D. Anderson Cancer Center

2008, Active, Medical University of South Carolina Hollings Cancer Center

Other Experience:

1999-2000, Senior Fellow, University of Texas M.D. Anderson Cancer Center, Medical Oncology

2001, Chief Fellow, LBJ Hospital Community Oncology Program

ASCO/AACR Methods in Clinical Cancer Research Workshop, Vail, Colorado, 2001

Southwest Oncology Group Young Investigators Training Course, 2001

Membership in professional/scientific societies (include offices held):

National Societies

2005 ASCO Gastrointestinal Cancers Symposium Program Committee; Chair, Pancreas-Hepatobiliary Subcommittee

Southwest Oncology Group (SWOG) Gastrointestinal Committee, Co-Chairman, Hepatobiliary Subcommittee 2004-Present

ASCO Scientific Programs Committee, Non-colorectal Gastrointestinal Cancers 2006-2007

American Association for the Study of Liver Disease (AASLD)

American Association for Cancer Research

American Society of Clinical Oncology

CanLiv, The Hepatobiliary Cancers Foundation, President

Local Societies

Medical Advisory Committee. South Texas Chapter, American Liver Foundation, 2006-2008

Editorial Positions:

2001-2006 Reviewer, *Cancer*

2002-2003 Reviewer, *Annals of Surgical Oncology*

2003-2004 Reviewer, *International Journal of Gastrointestinal Cancer*

2004-2005 Reviewer, *Clinical Cancer Research*

2004-2005 Reviewer, *Journal of Clinical Oncology*

2004 Reviewer, *Molecular Carcinogenesis*

Extramural Grants/award amount (current and past):

Principal Investigator, ASCO Foundation Clinical Research Career Development Award 2004
"Targeted Therapies for Biliary Cancer" 3-year award \$170,000

Co-Investigator, NIH T32 Training Grant for Academic Oncologists/Hematologists 2001-2002

Principal Investigator, "A Dose-Finding, Safety, and Pharmacokinetic Study of the Epidermal Growth Factor receptor Tyrosine Kinase Inhibitor, OSI-774 (NSC 718781) in Patients with Unresectable Hepatocellular Carcinoma and Moderate Hepatic Dysfunction", NCI, IDo1-510

Principal Investigator, "A Phase 2 Open-Label Study of OSI-774 (NSC 718781) in Unresectable Hepatocellular Carcinoma," NCI, IDO2-008

Principal Investigator, "Phase I Study to Determine the Safety and Pharmacokinetics of 4-Hour Intravenous Infusion of TAS-106 on a Once Per Week for 3 Consecutive Weeks Every 28 Day Schedule in Patients with Solid Tumors (TAS-106 9903)," DM02-740

Principal Investigator, "A Phase II Study of Oxaliplatin and Capecitabine in Patients with Unresectable Cholangiocarcinoma, including Carcinoma of the Gallbladder and Biliary Tract," Sanofi-Winthrop, 2003-0340

Principal Investigator, "Laboratory Protocol for Collection of Residual Tissue and Sample Analyses from Patients with Cholangiocarcinoma (Gallbladder and Biliary Cancer Tract)," Lab03-0412

Principal Investigator, "A Phase I Pharmacokinetic Study of Etoposide B Analogue BMS-247550 (NSC-710428D) in Patients with Advanced Malignancies and Varying Levels of Liver Dysfunction (S0355)," SWOG S0355

Principal Investigator, "Analysis of Fibrosis Differentiation in Patients with Hepatocellular Carcinoma Treated with TAC-101," Lab05-0100

Principal Investigator, "Retrospective Chart Review to Collect Additional Data on Patients Enrolled on ID-01-007 A Phase I/II, Single Center Dose Escalation, Pharmacokinetic, Safety, and Efficacy Study of Oral TAC-101 in Patients with Advanced Hepatocellular Carcinoma," RCR06-0599

Principal Investigator, "A Phase II Study of the Combination of Bevacizumab and Erlotinib in Patients with Unresectable Hepatocellular Carcinoma" Investigator-sponsored trial, Genentech, 2004-0874

Principal Investigator, (U.S. and International Trial) A Randomized 2-Arm, Open Label, Phase II Study of BMS5-582664, Administered Orally at a Dose of 800 mg Daily or Doxorubicin Administered Intravenously at a Dose of 60mg/m² Every Three Weeks in Patients with Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma," BMS-sponsored trial, 2006-0860

Principal Investigator, "A Phase II Study Trastuzumab (NSC 688097) in Her2/neu Positive Cancer of the Gallbladder or Biliary Tract" NCI (NCI 7756) supported trial, 2006-0851

Principal Investigator, "Phase I/II Single-Center, Dose Escalation, Pharmacokinetic, Safety, and Efficacy Study of Oral TAC-101 in Patients with Advanced Hepatocellular Carcinoma", Taiho Pharmaceutical Co. Ltd., IDO1-007,

Principal Investigator, 2004-0749, "A Retrospective Analysis of Tissue Cofactors that May be Predictive of Response to TAC-101, an Oral Synthetic Retinoid, in Patients with Hepatocellular Cancer Previously Treated with TAC-101 on Clinical Protocol ID01-007," Taiho Pharmaceutical Co. Ltd., 2004-0749

Principal Investigator, "Phase II Study of BAY 43-9006 (NSC # 724772) as Single Agent in Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma," SWOG SO514

Principal Investigator, "Phase II Open-Label Study of Weekly Taxoprexin (DHA-Paclitaxel) Injection as Second Line Therapy for Patients with Advanced Primary Cancers of the Liver, Incl. Hepatocellular Carcinoma (HCC) & Carcinoma of The Gallbladder or Biliary Tract (BTC) (P01-05-23), Luitpold, 2006-0566

Principal Investigator (HCC-MUSC) "A Phase 2, Double-Blind, Placebo-Controlled, Randomized, International, Multicenter Study of Oral Tac-101 as Second Line Treatment in Patients with Advanced Hepatocellular Carcinoma who Received Sorafenib as First Line Therapy" January 2009 \$144,775.00

Principal Investigator (HCC-MUSC) "A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma (HCC)" January 2009 \$3,543,036.00

Associate Director, Medical University of South Carolina Cancer Center Support Grant. 1P30CA138313-01 (Kraft) NIH/NCI. 5 year award. April 2009, \$1,475,000.00, 20%

Intramural Grants/amount of award:

Awards, Honors, membership in Honorary Societies:

May 1996 Esther B. and Arthur Kahn Memorial Scholarship Award,
Boston University School of Medicine

June 2004 ASCO Foundation Clinical Research Career Development Award 2004,
"Targeted Therapies for Biliary Cancer" 3-year award \$170,000

Academic Committee Activities (past 5 years):

Member, IND Review Committee, M.D. Anderson Cancer Center 2006-2008

Chairperson, Clinical Research Committee II 2005-2008

Member, Quality Management Committee, 2006-2008

Associate Member, Institutional Review Board, 2007-2008

Major Teaching Responsibilities (current):

Continuing Medical Education

GlaxoSmithKline National Oncology Fellows Forum “Phase II Trial of Eloxatin (Oxaliplatin) and CPT-11 Administered Once Every Three Weeks to Patients With Metastatic Colorectal Cancer (MCC)”, Phoenix, AZ, Feb. 2002

Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Texas Medical Branch “Hepatocellular Carcinoma – An Oncologists View”, Galveston, TX, March 2002

The M.D. Anderson Research Program Presentation to Singapore Economic Development Board “Hepatocellular Carcinoma”, August 2002

In-service teaching for GI Center nursing staff “Diagnosis and Management of Hepatocellular Carcinoma”, February 2003

Post-ASCO Breast and Gastrointestinal Cancer Symposium “Developments in the Management of Pancreatic Cancer”, Austin, TX, July 2003

Surgical Grand Rounds, M.D. Anderson Cancer Center “Medical Management of Primary Liver Tumors”, October 2003

Park Plaza Hospital Institutional Grand Rounds “Pathogenesis and Etiology of Hepatocellular Cancer”, Houston TX, June 2004

First Annual M.D. Anderson Cancer Center – Clinica Alemana Workshop in Gallbladder Cancer “Models of Carcinogenesis in Gallbladder and Biliary Cancer” and “Systemic Therapy for Biliary Tract Cancer”, Santiago, Chile, June 2004

Update on the Management of Gastrointestinal Malignancies “Treatment Options for Hepatocellular and Biliary Cancers”, Colorado Springs CO, July 2004

Medical Oncology Fellowship program lecture “Diagnosis, Etiology and Management of Hepatobiliary Tumors”, September 2004

Contemporary Concepts in Liver Disease and Transplantation “Non-Surgical Management of Liver Tumors”, Houston, TX, November 2004

Baylor College of Medicine, Hematology/Oncology Fellows Lecture Series “Management of Primary Liver Malignancies”, January 2005

Institutional Grand Rounds “Reactivation of Hepatitis B Virus in Cancer Patients”, October 2005

Institutional Grand Rounds “Targeted Therapies for Biliary Tract Cancers”, May 2006

Baylor College of Medicine, Oncology Fellows Lecture Series “Carcinoma Hepatocellular Cancer”, October 2007

Internal Medicine Grand Rounds, Sanford School of Medicine, University of South Dakota “Hepatocellular Carcinoma – Evidence-Based Multidisciplinary Management”, November 2007

Lectures and Presentations:

Invited lectures and presentations

ASCO Gastrointestinal Cancers Symposium “Translational Research in Systemic Therapy for Gallbladder Cancer Using a Transgenic Mouse Model”, Miami, FL, January 2005

5th Annual Oncology Update: Advances and Controversies “Rational Approach to the Treatment of Patients with Unknown Primary Cancers”, Park City, UT, January 2005

2nd Annual Update on Management of GI Cancers “Treatment of Hepatobiliary Malignancies”, San Diego, CA, October 2005

Round Top 2006 – Gastrointestinal Cancer: Advances in Biology and Therapy “Amplification of Epidermal Growth Factor Receptor (EGFR) and erbB2 (HER-2/neu) Gene Expression in Gallbladder and in Bile Duct Cancer (BTC): Therapeutic Implications”, Round Top, TX, April 2006

M.D. Anderson Sister Institution Conference “Targeted Therapies for Cancers of the Gallbladder and Biliary Tract”, Houston, TX, June 2006

American Society of Clinical Oncology Annual Meeting, “Amplification of HER2neu gene in cancers of the gallbladder and biliary tract”, Oral Abstract Platform Presentation, Atlanta, GA, June 2006

Invited Speaker, World GI Conference “Targeted Therapies in Hepatocellular Cancer”, Barcelona, Spain, June 2006

Universidad de la Frontera, Medicine Grand Rounds, “Biologic Characteristics of Gallbladder and Biliary Cancers and Targeted Therapies” Temuco Chile, SA April 2007

Clinica Alemana Oncology Grand Rounds, “Management of Gallbladder and Biliary Cancer”, Santiago Chile, SA April 2007

5th International Meeting Hepatocellular Carcinoma: Eastern and Western Experiences Invited talk “Treatment of Multinodular HCC: Medical Therapy” January 2007, Houston TX

American Association for the Study of Liver Diseases (AASLD) Single Topic Conference “Endpoints in Clinical Trials for Hepatocellular Carcinoma” talk “New Agents in the Treatment of Advanced HCC” December 2007 Atlanta, GA

AASLD 2008 Henry M. & Lillian Stratton Basic Research Single Topic Conference: Pathobiology of Biliary Epithelia and Cholangiocarcinoma; “Opportunities for Targeted Therapies in Cholangiocarcinoma” Atlanta, Georgia, June 2008

94th Meeting of the Japanese Society of Gastroenterology, “Targeted Therapies for Hepatocellular Cancer” Fukuoka, Japan, May 2008

Tokyo Women’s University, Institute of Gastroenterology, “Biological Therapy of Hepatobiliary Cancers”, Tokyo, Japan, May 2008

The University of Texas M.D. Anderson Cancer Center and M.D. Anderson Physinans Network Fourth Annual Symposium “Emerging Strategies in Treatment of Hepatocellular Carcinoma” August 2008

The International Liver Cancer Association’s Second Annual Conference. “Emerging Molecules in HCC” and “A Phase I/II Trial of TAC101.” Chicago, IL, September 2008.

International Society of Gastrointestinal Oncology Conference. “Case presentation: Second line therapy in Hepatobiliary Cancer.” Arlington, VA. 2008

Medicine Grand Rounds. "Opportunities and Challenges in Developing Targeted Therapies for Cancer Patients." MUSC, Charleston, SC, September 2008

Colorectal Cancer CME, "Current Research and Emerging Treatments in Colorectal Cancer." Myrtle Beach, SC. October 2008

American Association for Cancer Research (AACR) International Conference: Infection and Cancer: Biology, Therapeutics and Prevention "Novel Targeted Therapies for Hepatocellular Carcinoma" Hong Kong, December 2008

Hepatocellular Carcinoma State of the Clinical Science Meeting, National Cancer Institute (NCI), "Advanced Hepatocellular Carcinoma – Potential New Molecular Targets" December 2008

GI Cancers Research Retreat. "Clinical research in hepatocellular carcinoma." Columbia, SC. January 2009

9th Liver Disease and Transplant Symposium. "Chemotherapy: The use of sorafenib and other new chemotherapeutic agents for hepatocellular carcinoma." Charleston, SC. February 2009

Submitted presentations

Glover K, **Thomas M**, Brown T, Hoff PM, Abbruzzese JL. A Phase II Study of Oxaliplatin and Capecitabine (XELOX) in Unresectable Cholangiocarcinoma. ASCO Poster Presentation 2005.

Kawamoto T, Kiguchi K, Ruffinino L, **Thomas M**, Wistuba I, DiGiovanni J. Gallbladder Carcinoma of BK5.erbB2 Transgenic Mouse Shares Molecular and Histopathologic Similarities to that of Humans. AACR poster presentation 2005.

Thomas M, Brown T, Patt Y, Hoff PM, Arima T, Abbruzzese J. A Phase I/II Dose-Escalation, Pharmacokinetic and Efficacy Study of Oral TAC101 in Patients with Advanced Hepatocellular Cancer (HCC). ASCO Gastrointestinal Cancers Symposium San Francisco, CA 2006.

Thomas M, Kawamoto K, Tarco E, Trivedi S, Krishnamurthy S. Amplification of erbB2 (HER2/neu) gene expression in gallbladder (GB) and bile duct cancer (BDC). ASCO Gastrointestinal Cancers Symposium San Francisco, CA 2006.

Sun W, Schwartz J, Zhu A, Philip D, Metz J, **Thomas M**. Feasibility of a Multi-institutional Liver Cancer Registry. ASCO Poster Presentation, Atlanta, GA 2006.

Thomas MB, Iwasaki M, Higginbotham K, Glover KY, Abbruzzese JL. A Phase II Study of the Combination of Bevacizumab and Erlotinib in Patients with Unresected Hepatocellular Carcinoma. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Poster Presentation, Prague, Czech Republic, November 2006.

Hassan M, Zhang WQ, Ahmed MI, Curley S, Vauthey N, Ellis L, Patt YZ, **Thomas M**, Brown T, Abbruzzese JL, Li D. C262T Polymorphism of the Catalase gene and Susceptibility to Hepatocellular Carcinoma. AACR Annual Meeting, Los Angeles, April 2007.

Thomas MB, Iwasaki M, Lozano, R., Glover KY, Abbruzzese JL. A Phase II Study of the Combination of Bevacizumab and Erlotinib in Patients with Unresected Hepatocellular Carcinoma. ASCO Poster Presentation Annual Meeting, Chicago IL, June 2007.

Kase, A, , Javle, M . Oniseacu, G , Garret-Mayer, E . **Thomas**, , MB University of Texas M.D. Anderson Cancer Center Houston TX ' Hollings Cancer Center Medical University of South Carolina. The Combination of Bevacizumab (B) and Erlotinib (E) Shows Significant Biological Activity in Patients with Advanced Hepatocellular Carcinoma (HCC). ASCO Annual Meeting 2009, Orlando FL. Poster Discussion, Non-colorectal Cancer

Extramural Professional Activities:

NCI GI-Intergroup Hepatobiliary Task Force member 2007-

Southwest Oncology Group (SWOG) Gastrointestinal Committee, Co-Chairman, Hepatobiliary Subcommittee 2004-Present

Invited Participant, European Association for the Study of the Liver, American Association for the Study of Liver Disease, Japan Society of Hepatology (**EASL-AASLD-JSH**)-Consensus Conference, Clinical Management of Hepatocellular Carcinoma, Barcelona, Spain, June 2005

American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium Program Committee, Pancreas-Hepatobiliary Subcommittee, 2004-2006

ASCO Scientific Program Committee member, Gastrointestinal Cancer, Non-colorectal, 2006-2007

ASCO Education Committee member, Gastrointestinal Cancer, Non-colorectal, 2008-2010

Chairperson, Hepatobiliary session, M.D. Anderson Sister Institution 2nd Annual Conference June 2006

Member, Organizing Committee, Fifth International Meeting. Hepatocellular Carcinoma: Eastern and Western Experiences, January 11-13, 2007

Community Service:

President, CanLiv – The Hepatobiliary Cancers Foundation, not for profit organization. www.canliv.org/canliv.

Publications:

Peer-Reviewed Journals

1. **Thomas MB**, Koller C, Yang Y, Shen Y, Kantarjian H, Davis J, Estey E. Comparison of Fludarabine-containing Salvage Chemotherapy Regimens for Relapsed/Refractory Acute Myelogenous Leukemia. *Leukemia* 17:990-993, 2003.
2. Pawlick T, Scoggins C, **Thomas MB**, Vauthey JN. Advances in the Surgical Management of Liver Malignancies. *Cancer J* 10:74-87, 2004.

3. **Thomas MB**, Zhu AX. Hepatocellular Carcinoma: The Need for Progress. *Journal of Clinical Oncology* 23:13 2892-2899, 2005.
4. **Thomas MB**, Abbruzzese JL. Opportunities for Targeted Therapies in Hepatocellular Carcinoma. *Journal of Clinical Oncology* 23:31, 2005.
5. Kelloff GJ, Lippman SC, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papdimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, **Thomas M**, Rhodes HE, Brewer MA, Follen M, Shin D, Parnes HL, Siegfried J, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL, O'Shaughnessy JO, Hawk ET, Levin B, Nelson WG, Hong WK. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia (IEN) and Cancer. AACR Cancer Prevention Task Force, *Clinical Cancer Research* 12:3661-3697, 2006.
6. Ribero D, Abdalla EK, **Thomas MB**, Vauthey, JN. Liver Resection in the Treatment of Hepatocellular Carcinoma. *Expert Review of Anticancer Therapy* 6(4):567-579, 2006.
7. **Thomas MB**. Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy. *Critical Reviews in Oncology/Hematology* 61(1):44-51, 2007.
8. Habib Y, El-Serag H, **Thomas M**, Hassan M. HCV and Cholangiocarcinoma in the USA, Case-Control Study. *American Journal of Gastroenterology* 102:1-6, 2007.
9. Shaib YH, El-Serag HB, Nooka AK, **Thomas M**, Brown TD, Patt YZ, Hassan MM. Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a hospital;-based case-control study. *American Journal of Gastroenterology* 102(5):1016-1021.
10. Wu Q, Kiguchi K, Kawamoto T, Ajiki T, Traag J, Carbajal S, Ruffino L, Thames H, Wistuba I, **Thomas M**, Vasquez KM, DiGiovanni J. Therapeutic Effect of Rapamycin on Gallbladder Cancer in a Transgenic Mouse Model. *Cancer Research* 67:3794-3800, 2007.
11. Ribero D, Wang H, Donadon M, Zorzi D, **Thomas MB**, Eng C, Chang DZ, Hamilton SR, Ellis LM, Curley SA, Abdalla EK, Vauthey JN. Bevacizumab Improves Pathologic Response and Protects against Hepatic Injury in Patients Treated with Oxaliplatin-based Chemotherapy for Colorectal Liver Metastases. *Cancer* 110(12):2761-2767, 2007.
12. **Thomas MB**, O'Beirne JP, Furuse J, Anthony MD, Chan TC, Abou-Alfa G, Johnson P. Systemic Therapy for Hepatocellular Carcinoma. *Annals of Surgical Oncology* 15(4):1008-1014, 2008.
13. Miyaharja N, Shoda J, Ishida H, Kawamoto T, Ueda T, Hyodo I, Ohkochi N, Yamamoto T, **Thomas MB**, Krishnamurthy S, Carraway KL, Irimura T. MUC4 Interacts with ErbB2 in Human Gallbladder Carcinoma: Potential Pathobiological Implications. *European Journal of Cancer* 44(7):1048-1056.
14. Kawamoto T, Krishnamurthy S, Tarco E, Trivedi S, Wistuba II, Li D, Roa JC, **Thomas MB**. HER Receptor Family: Novel Candidate for Targeted Therapy for Gallbladder and Extrahepatic Bile Duct Cancer. *Gastrointestinal Cancer Research* 1(6):221-227, 2007.

15. **Thomas MB**, Chadha R, Glover, K, Wang X, Morris J, Brown T, Rashid A, Dancey J, Abbruzzese JL. A Phase II Study of Erlotinib (OSI 774) in Patients with Unresectable Hepatocellular Carcinoma. *Cancer* 110(5):1059, 2007.
16. **Thomas MB**, Tetzlaff E, Lozano R, Samp L, Butler C, Gannon C, Hamilton S, Vauthey JN, Abdalla E. Curing Hepatocellular Carcinomatosis with Biologic Therapy and Surgery: Achieving the Impossible? *Journal of Surgical Oncology* 97:82-84, 2008.
17. **Thomas MB**. Targeted Therapies for Cancer of the Gallbladder *Current Opinion in Current Opinion in Gastroenterology* 24:372-376, 2008.
18. **Thomas MB**. Systemic Therapy for Hepatocellular Carcinoma. *The Cancer Journal*, Theodore S. Lawrence and Melanie B. Thomas, Guest Editors, *The Cancer Journal* 14(2):123-127, 2008.
19. **Thomas MB**, Davila M, Abbruzzese JL. Stemming the Tide of Hepatitis B Virus-Related Hepatocellular Carcinoma. *Journal of Clinical Oncology* 26(2):172-174, 2008.
20. **Thomas, M.B**, O'Beirne, J.P., Furuse, J., Chan, A.T.C., Abou-Alfa, G., Johnson, P. Systemic Therapy for Hepatocellular Carcinoma: Cytotoxic Chemotherapy, Targeted Therapy and Immunotherapy. *Annals of Surgical Oncology* 15(4):1008-1014 April 2008.
21. Miyahara N, Shoda J, Ishige K, Kawamoto T, Ueda T, Taki R, Ohkohchi N, Hyodo I, **Thomas MB**, Krishnamurthy S, Carraway KL, Irimura T. MUC4 interacts with ErbB2 in human gallbladder carcinoma: potential pathobiological implications. *European Journal of Cancer*. 2008 May; 44(7):1048-1056.
22. Manal M. Hassan, Margaret R. Spitz, **Melanie B. Thomas**, Adel S. El-Deeb, Katrina Y. Glover, Nga T. Nguyen, Wenyaw Chan, Ahmed Kaseb, Steven A. Curley, Jean-Nicolas Vauthey, Lee M. Ellis, Eddie Abdalla, Richard D. Lozano, Yehuda Z. Patt, Thomas D. Brown, James L. Abbruzzese and Donghui Li. Effect of different types of smoking and synergism with Hepatitis C virus on risk of hepatocellular carcinoma in American men and women: Case-control study. *Int. J. Cancer*: 2008 Oct 15; 123(8): 1883-1891.
23. Higginbotham KB, Lozano R, Brown T, Patt Y, Arima T Abbruzzese JL, **Thomas MB**. A Phase I/II trial of TAC-101, an Oral Synthetic Retinoid, in Patients with Advanced Hepatocellular Carcinoma. *Journal of Cancer Research and Clinical Oncology*. 2008 Dec; 134(12):1325-35.
24. Manal M. Hassan , Donghui Li, Yehuda Z. Patt, Jean-Nicolas Vauthey, **Melanie B. Thomas**, Steven A. Curley , Margaret R. Spitz , Eddie K. Abdalla , Marta Davila , Richard D. Lozano, Deena M. Hassan, Wenyaw Chan, Ahmed Kaseb, Thomas D. Brown, James L. Abbruzzese. Association Between Hypothyroidism and Hepatocellular Carcinoma: USA case-control study. *Journal of Hepatology*. 2008 Dec 23; 9999(99A).
25. **Melanie B. Thomas**, Jeffrey S. Morris, Romil Chadha, Michiko Iwasaki, Harmeet Kaur, Elinor Lin, Ahmed Kaseb, Katrina Glover, Marta Davila, and James Abbruzzese. A

Phase II Trial of the Combination Bevacizumab and Erlotinib in Patients with Advanced Hepatocellular Carcinoma. *Journal of Clinical Oncology*, 2009 Jan; 27 (6).

26. Hideo, Suzuki, Juan C. Roa, Toru Kawamoto, Kazunori Ishige, Junichi Shoda, Ichinosuke Hyodo, Ignacio I. Wistuba, Donghui Li, **Melanie B. Thomas**. The Expression of Insulin like Growth Factor Receptor (IGFR) as a useful prognosis predicting biomarker in biliary tract cancer. Submitted to *Cancer Research*, 2009 January.
27. **Thomas, M.B.** Molecular Targeted Therapy for Hepatocellular Carcinoma. *Journal of the Japanese Society of Gastroenterology*. 2009 January 16. 44(19):136-141.
28. Hassan MM, Spitz MR, **Thomas MB**, Curley SA, Patt YZ, Vauthey JN, Golver KY, Kaseb A, Lozano RD, El-Deeb AS, Nguyen NT, Wei SH, Chan W, Abbruzzese JL, Li D. The Association of Family History of Liver Cancer with Hepatocellular Carcinoma: A case-control study in the United States. *Journal of Hepatology*. 2009 February; 50(2):247-8

Chapters in Scholarly Books and Monographs

1. **Thomas M**, Hoff PM. Oral Fluoropyrimidines in Colorectal Neoplasia. In: *Colorectal Cancer*, 2nd edition. Martin-Dunitz Publishers, London 2001.
2. **Thomas M**, Abbruzzese JL. Carcinoma of Unknown Primary. In: *Current Cancer Therapeutics*, Fourth Edition. 2001.
3. **Thomas M**, Wolff RA. Current Understanding of Colo-Rectal Neoplasia. In: *Colonic Diseases*, ed. Koch TR. The Humana Press Inc. 2003.
4. **Thomas M**, Abbruzzese JL. Cancer of Unknown Primary. In: *Clinical Practice of Hematology and Oncology: Presentations, Diagnosis and Treatment*. Furie, Mayer, Cassileth, Atkins (eds) 2003.
5. **Thomas MB**, Abbruzzese JL. A Man with Painless Jaundice. In: *Patient of the Month Program in Oncology CD ROM*. BC Decker Electronic Publishing, July 2004.
6. **Thomas MB**, Wolff RA. Colorectal Cancer: Diagnosis and Management. In: *The M.D. Anderson Manual of Clinical Oncology*. McGraw-Hill 2005.
7. Chang B, **Thomas MB**, Wolff RA. Primary Liver Malignancies. In: *The M.D. Anderson Manual of Clinical Oncology*. McGraw-Hill 2005.
8. Pawlik TM, **Thomas M**, Vauthey JN. Management of hepatocellular carcinoma. In: *Advanced Therapy in Gastroenterology and Liver Disease 5th Edition*. Bayless TM, Diehl AM (eds). BC Decker Inc. London, England, 2005; pp 739-743.
9. Kaseb A, **Thomas MB**. Chemotherapy and Novel Therapies. In: *Hepatocellular Carcinoma: A Practical Approach*. Al Knawy B, Reddy KR, Bolondi L (eds), in press, 2008.

Other Publications:

1. Pawlik TM, Abdalla EK, **Thomas M**, Roh MS, Lauwers GY, Ribero D, Poon RT, Belghiti J, Nagorney DM, Vauthey JN. Staging of Hepatocellular Carcinoma. Letter to the Editor, Hepatology 2005 42(3):738-739; author reply 739-740.
2. **Thomas MB**, Abdalla EK. Patient Guide to Cancers of the Liver and Biliary Tract. J.W. Covenant, Inc., Woodlands, Texas, May 2007.

Other Appointments/Responsibilities

Consultantships

Speakers Bureaus: Lilly, GENIE (Genentech Integrated Education), VERN (Vascular Endothelial Research Network), 2004 - Present

Bayer Health Care, consultant 2005 Co-Moderator, Advisory Board, Bayer Oncology International Phase III Clinical Trial of Sorafenib in Hepatocellular Carcinoma June 2005, Barcelona, Spain

Bristol Myers Squibb Pharmaceutical Research Institute – consultant 2006
Co-chair International Advisory Board on the Clinical Development of BMS 582664 in Hepatocellular Cancer, Boston Massachusetts, October 2006

Genentech BioOncology consultant 2006
Co-chair, International Advisory Board on the Clinical Development of bevacizumab and erlotinib in hepatocellular carcinoma Paris, France, October 2006

Taiho Pharmaceutical Co Ltd, Consultant 2006, Clinical Development of TAC-101 in Hepatocellular Carcinoma

Grant Reviewer/Service on NIH/Other Study Sections

June 2003 Reviewer, GI Oncology Grant Proposals, FDA Orphan Drug Program
Washington D.C.

Supervisory Teaching

Direct Supervision

Continuity Clinic Faculty Mentor for Dr. Kimberly Higginbotham, 2005-2006

Faculty Advisor for Dr. Debra Patt, Medical Oncology Postdoctoral Fellow, 2003-2006

ASCO/AACR Methods in Clinical Cancer Research Workshop, Vail, Colorado, 2001

Southwest Oncology Group Young Investigators Training Course, 2001